Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Jazz Pharmaceuticals
Pharma
Jazz’s Ziihera nets FDA nod in first-line HER2+ stomach cancer
Jefferies analysts recently put Ziihera’s peak sales at $1.5 billion in gastroesophageal adenocarcinoma alone.
Angus Liu
Aug 25, 2026 11:06am
Jazz to withdraw Zepzelca in second-line small cell lung cancer
Aug 4, 2026 9:18am
Novartis’ ‘Relax Your Tight End’ wins Cannes Pharma Grand Prix
Jun 23, 2026 9:06am
Zepzelca saga takes another turn with ph. 3 lung cancer flop
Jun 12, 2026 10:48am
Beaches, birds and more—a tour of ASCO’s exhibit hall floor
Jun 3, 2026 1:28pm
Alkermes’ Lumryz, from $2.4B Avadel buy, hits phase 3 mark in IH
May 12, 2026 11:45am
